Updates are available Correction dated 2025-09-16
Click to view Correction: https://doi.org/10.1186/s13054-025-05645-8
-
Authors
Wagner, Adam P.
Enne, Virve I.
Gant, Vanya
Stirling, Susan
Barber, Julie A.
Livermore, David M.
Turner, David A.
,
Ahmed, Naseem
Akinkugbe, Olugbenga
Aman, Zoran
Aramburo, Angela
Bercades, Georgia
Brealey, David
Bull, Rhian
Cassidy, Jane
Carungcong, Jaime
Cherian, Benny P.
Colles, Antony
da Costa, Patricia Correia
Cuesta, Jeronimo
Dhesi, Zaneeta
Dresser, Kerry
Dryden, Matthew
Filipe, Helder
Gellamucho, Minnie
Hass, Ingrid
High, Juliet
Horne, Robert
Kandil, Hala
Karlikowski, Michael
Klein, Nigel
Liyanage, Kamal
Mack, Damian
Milner, Philip
Mingo, Sara Garcia
Martin, Daniel
Moore, Luke
Mughal, Nabeela
de Neef, Mark
North, Julie
O’Grady, Justin
O’Neill, Lauran
Page, Valerie
Pandolfo, Alyssa
Parker, Robert
Patel, Nehal
Patel, Pooja
Peters, Mark
Pipi, Giovanni
Reid, Karen
Ricciardi, Federico
Riley, Peter
Russell, Charlotte
Shallcross, Laura
Shaw, David
Singh, Suveer
Simpson, Ruan
Sonksen, Julian
Stewart, Sarah-Jane
Smyth, Deborah
Swart, Ann Marie
Tan, Jenny
Tooke, Carly
Tous, Laura
Tudtud, Eleanor
Turner-Bone, Ian
Wang, Justin
Waugh, Victoria
Welters, Ingeborg D.
Wilding, Laura
Winmill, Helen
Williams, Karen
Zhao, Xiaobei
-
Clinical Trials BETA
Clinical trials referenced in this document:
isrctn16483855 at ISRCTN.orgDocuments that mention this clinical trial
Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study
https://doi.org/10.1136/thoraxjnl-2021-216990
Cost-effectiveness of rapid, ICU-based, syndromic PCR in hospital-acquired pneumonia: analysis of the INHALE WP3 multi-centre RCT
https://doi.org/10.1186/s13054-025-05428-1
Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework
https://doi.org/10.1136/bmjqs-2020-012479
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 22 April 2025
First Online: 8 August 2025
Change Date: 16 September 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13054-025-05645-8
Declarations
:
: As noted in the main clinical paper [] ethics approval was from the London-Brighton and Sussex Research Ethics Committee (19/LO/0400). Consent was deferred: adult patients or their consultees were approached for written consent or assent as soon as possible after randomisation. When incapacitated patients regained capacity they were approached for retrospective consent directly. For children, parents or guardians were approached for consent, and older children were approached for assent. The INHALE WP3 trial was registered as ISRCTN16483855 on 5th August 2019.
: Not applicable.
: VE reports consultancy and speaker fees from bioMérieux, personal fees from Alchemab Therapeutics, and in-kind contributions from Inflammatix Inc. VG reports speaker fees from bioMérieux and consultancy fees from Gilead, MSD, Pfizer and Shionogi. DML reports personal fees from Adjutec, AstraZeneca, bioMérieux, Centauri, GenPax, GSK, Hikma, Merck/MSD, Nordic, Paion, Pfizer, Shionogi, Sumitovant, Summit, Thermofisher, and Zambon. He also reports shareholdings from GenPax, GSK, Merck, and PerkinElmer/Revvity, comprising less than 10% of portfolio value. He also has nominated holdings in Arecor, Celadon Pharmaceuticals, Destiny Pharma, Eluceda Ltd., Genedrive, Poolbeg, Optibiotix, Probiotix Health, SkinBiotherapeutics, Trellus and Verici Dx (all of which have research/products pertinent to medical and diagnostic innovation) through Enterprise Investment Schemes but has no authority to trade these shares directly. All are outside the submitted work. All other authors declare no competing interests.
